25 Jan 2008 - DIREVO Biotech AG announced the signing of a research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop a therapeutic protease for the treatment of CNS diseases.
Under the terms of the agreement, Direvo will be applying its proprietary protein-engineering capabilities to create specifically engineered proteases. MedImmune will then be responsible for the development and marketing of the protease product that may arise under the agreement. Direvo will receive undisclosed upfront and milestone payments, as well as research funding plus royalties on potential sales of the therapeutic protease should it reach the market.
 |
www.bionity.com/news/e/76950 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/76950 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |